Nektar Therapeutics
NKTR
$73.32
-$2.12-2.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -40.62M | -44.90M | -36.08M | -35.52M | -41.59M |
| Total Depreciation and Amortization | 156.00K | 151.00K | 190.00K | 196.00K | 214.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.81M | 523.00K | -5.95M | -3.27M | -778.00K |
| Change in Net Operating Assets | -32.49M | -68.00K | -23.12M | -10.17M | -3.58M |
| Cash from Operations | -75.77M | -44.30M | -64.96M | -48.76M | -45.74M |
| Capital Expenditure | -94.00K | -18.00K | -715.00K | -114.00K | -37.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -399.02M | -350.77M | 1.09M | -94.76M | 49.65M |
| Cash from Investing | -399.11M | -350.79M | 372.00K | -94.87M | 49.62M |
| Total Debt Issued | 13.58M | 93.12M | 38.26M | 142.59M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 878.00K | 4.06M | 410.00K | 238.00K | 211.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 350.11M | 432.38M | 0.00 | -1.15M | -- |
| Cash from Financing | 364.57M | 529.55M | 38.67M | 141.68M | 211.00K |
| Foreign Exchange rate Adjustments | -- | -- | 0.00 | 1.00K | 6.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -110.31M | 134.46M | -25.92M | -1.96M | 4.09M |